Brexit and the Falsified Medicines Directive

In order to help patients avoid being exposed to falsified medicines, the European Commission developed a series of measures to support patients in identifying licenced suppliers of pharmaceutical medicines, and suppliers to identify whether an end-user pack of medicines was genuine. The measures outlined in the Falsified Medicines Directive (2011/62/EU) have been applied across the European Union (EU), with […]

ETP in Europe: the case of UK, Estonia, Denmark, and Sweden

A report has just been published with cross-country comparison of implementations of electronic transmission of prescriptions: “European e-Prescriptions: Benefits and Success Factors”, by Ulrike Deetjen.

The report describes the economic, health, and societal benefits of e-prescriptions, within different policy structures. Based on previous evidence and expert interviews for case studies of Estonia, the United Kingdom, Denmark, and Sweden, it derives […]

July 14th, 2016|Policy|0 Comments|

The EU Personalised Medicine Observatory (2011-2014?)

Part of the EuroBioForum, the Observatory gives insight into the ‘key players’ in Personalised Medicine in Europe, with an online database publicly available of initiatives per country and/or topic.



EuroBioForum is funded by the European Commission (DG Research & Innovation), 7th Framework Programme. 
Grant Agreement Number: HEALTH-F4-2010-261453
Duration: 1 January 2011 – 31 December 2014

Implementing transparency at the European Medicines Agency

Sergio Bonini, M.D., Hans-Georg Eichler, M.D., Noël Wathion, Pharm., and Guido Rasi, M.D., explain EMA’s policy and practice  about transparency and sharing of data from clinical trials. In:

Transparency and the European Medicines Agency — Sharing of Clinical Trial Data

N Engl J Med 2014; 371:2452-2455December 25, 2014

January 8th, 2015|Regulation, Research|0 Comments|

On value base pricing and uncertainty of cost-effectiveness

A new study by colleagues at LSE, Alessandra Ferrario and Panos Kanavos:

Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden, Social Science & Medicine, Volume 124, January 2015, Pages 39-47,

Available at:

A combination of high prices of new patented medicines, […]

November 24th, 2014|Regulation, Value|0 Comments|

Drug pricing in Europe (In French, from Le Monde)

This article from Le Monde explains how medicines are priced in Europe.
Comment est fixé le prix d’un médicament

Especially of relevance the part about really innovative medicines: “pour les produits les plus innovants – une dizaine par an  –, autorisés au niveau européen et qui obtiennent une note élevée de la part de la Commission de la transparence, le prix […]

October 1st, 2014|Value|0 Comments|

On medicines supply – Drug shortages in European countries

A new paper on the problem of drug shortages and the sustainability of the medicine market:

Drug shortages in European countries: a trade-off between market attractiveness and cost containment?

by Kim Pauwels, Isabelle Huys, Minne Casteels and Steven Simoens
BMC Health Services Research, 2014, 14 :438

Drug shortages are a global problem. While extensively studied in the United States, numbers about drug […]

October 1st, 2014|Regulation, Value|0 Comments|

News: Interpol raid on illegal medical drugs trade [in French]

From Le Monde:

Raid historique d’Interpol contre les pharmacies en ligne

‘D’après un rapport de la Commission européenne paru en 2012, les médicaments contrefaits sont ainsi les premiers produits saisis aux frontières de l’Union européenne via le trafic postal.
… Dans le monde, 6 % à 15 % du marché mondial de médicaments relève de la contrefaçon, selon l’Organisation mondiale […]

Europe Innovative Medicines Initiative (IMI)

The Innovative Medicines Initiative (IMI) is Europe’s largest public-private partnership aiming to improve the drug development process by supporting a more efficient discovery and development of better and safer medicines for patients. The legislation establishing IMI 2 was approved by the EU Member States on 6 May 2014. IMI 2 will be launched later in 2014 and will run […]

May 9th, 2014|Research|0 Comments|